Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 5.3% in the afternoon session after an SEC ...

Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2026 financial results on Tuesday, May 5, 2026. The Company will issue a press release before the ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Repligen (RGEN) and Neurogene (NGNE) with bullish sentiments. Craig-Hallum analyst Matt Hewitt maintained ...

Repligen (RGEN) is back on investors’ radar after a recent move in its share price, with the stock closing at US$131.99. That shift invites a fresh look at its bioprocessing-focused business. See our ...

Fintel reports that on April 17, 2026, Roth Capital initiated coverage of Repligen (NasdaqGS:RGEN) with a Buy recommendation.

Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.

Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training & Innovation Center (“RTIC”) ...

The model offers better coding capabilities than Opus 4.6, but it is still not as good as Claude Mythos Preview.

Repligen stock snapshot and recent performance Repligen (RGEN) has drawn investor attention after recent trading left the shares around US$117.78, with the stock showing mixed returns over the past ...

This is Paul Knight, life science analyst at Repligen. And with us, we have Jacob Johnson, Head of Investor Relations; Jason, Chief Financial Officer; Olivier, CEO. We all very familiar with Repligen ...